BPC-157 + GHK-Cu + TB-500 + KPV

BPC-157 + GHK-Cu + TB-500 + KPV: A four-component blend containing 10 + 50 + 10 + 10 mg in the named order.

What is it?

A four-component blend containing 10 + 50 + 10 + 10 mg in the named order.

How it is studied

KPV adds another experimental inflammatory-signalling component to the BPC-157, GHK-Cu, and TB-500 combination.

What the evidence says

Ingredient-level mechanisms do not establish a tested interaction or clinical outcome for the combined formulation. Human evidence for this exact mixture is insufficient.

What remains uncertain

More components introduce additional identity and compatibility questions. The ratio must remain explicit. A commercial blend name does not establish safety or effectiveness for the whole product.

Sources & scope

Systematic review of musculoskeletal evidence (2025)

Maquart et al., experimental wound study (1993)

Thymosin beta-4 ophthalmic study

PepT1-mediated effects in inflammatory models (2008)

For in-vitro laboratory research only. Not for human or veterinary use.